BioVaxys Technology Corp. C.BIOV

biov chief med officer to present to v impt board

[Humanist]

BioVaxys Chief Medical Officer David Berd, MD, Invited by Editorial Board of Therapeutic Advances in Vaccines and Immunotherapy to Submit a Review Article on Haptenized Protein Vaccine Platform
 
BioVaxys Technology Corp. 
Nov 18, 2021, 08:41 ET

VANCOUVER, BC, Nov. 18, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), a clinical-stage immunotherapy company,  is pleased to announce that its Chief Medical Officer David Berd, MD, has been invited by the Editorial Board of Therapeutic Advances in Vaccines and Immunotherapy to submit a scientific review article based on his speaking engagement entitled "Haptenized Protein Vaccines for Viral Diseases and Cancer" on December 1^st at the World Vaccine & Immunotherapy Congress ("WVIC") in San Diego, CA.
Therapeutic Advances in Vaccines and Immunotherapy is a prestigious peer-reviewed journal focused on advances in the fields of vaccinology and immunotherapy, reporting on both prophylactic and therapeutic vaccination as well as other immunotherapeutic interventions. It has a strong clinical, immunological and translational focus, is PubMed, SCOPUS and ESCI-indexed, and is an official partner journal of WVIC. 
Scientific conferences and journal articles are critical for an open sharing of ideas and research results, and provide a way to attract scientific interest, research collaborations, and commercial interest.  "We are extremely pleased that Dr Berd is being commissioned to prepare a review article, especially for such a well-regarded publication," says Ken Kovan, President & Chief Operating Officer of BioVaxys

.  "As we have now significantly built our patent portfolio, we are in a better position to share our technologies more broadly within scientific community as we look for Principal Investigators for our upcoming clinical studies, and potential development partners."